Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:crizotinib
go back to main search page
Accession:CHEBI:64310 term browser browse the term
Definition:A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Synonyms:exact_synonym: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
 related_synonym: (R)-crizotinib;   Formula=C21H22Cl2FN5O;   InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1;   InChIKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N;   PF 2341066;   SMILES=C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl;   crizotinibum
 alt_id: CHEBI:77554
 xref: CAS:877399-52-5;   Drug_Central:4187;   KEGG:D09731;   LINCS:LSM-1027
 xref_mesh: MESH:C551994
 xref: PMID:21308771;   PMID:22129595;   PMID:22129984;   PMID:22191798;   PMID:22215748;   PMID:22233293;   PMID:22235099;   PMID:22277784;   PMID:22282074;   PMID:22311682;   PMID:22316363;   PMID:22321987;   PMID:22323827;   PMID:22385925;   PMID:22397764;   PMID:22435662;   PMID:22443113;   PMID:24427836;   PMID:24444403;   PMID:24455567;   PMID:24486291;   PMID:24491302;   PMID:24556908;   Reaxys:12133926;   Wikipedia:Crizotinib
 cyclic_relationship: is_enantiomer_of CHEBI:77555


show annotations for term's descendants           Sort by:
 
crizotinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
decreases activity
ISO crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]
crizotinib results in decreased activity of ABCB1 protein
CTD PMID:22233293, PMID:28369651 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 decreases activity ISO crizotinib results in decreased activity of ABCG2 protein CTD PMID:28369651 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase decreases activity ISO crizotinib results in decreased activity of ABL1 protein CTD PMID:21812414 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Acaca acetyl-CoA carboxylase alpha increases phosphorylation ISO crizotinib results in increased phosphorylation of ACACA protein CTD PMID:23707608 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation
multiple interactions
ISO crizotinib results in decreased phosphorylation of AKT1 protein
EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]
CTD PMID:22553343, PMID:22729845 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Alk ALK receptor tyrosine kinase decreases response to substance
affects response to substance
decreases activity
increases mutagenesis
decreases stability
decreases phosphorylation
multiple interactions
ISO ALK gene mutant form results in decreased susceptibility to crizotinib; ALK gene SNP results in decreased susceptibility to crizotinib; ALK protein mutant form results in decreased susceptibility to crizotinib
ALK protein affects the susceptibility to crizotinib
crizotinib results in decreased activity of ALK protein mutant form
crizotinib results in increased mutagenesis of ALK gene mutant form; crizotinib results in increased mutagenesis of ALK protein mutant form
crizotinib results in decreased stability of ALK protein mutant form
crizotinib results in decreased phosphorylation of ALK protein; crizotinib results in decreased phosphorylation of ALK protein mutant form
crizotinib results in decreased activity of ALK protein; crizotinib results in decreased activity of ALK protein mutant form
[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK gene mutant form] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK protein mutant form] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK protein mutant form] which results in increased activity of ALK protein; [Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]; [Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to crizotinib; ALK gene SNP inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein mutant form]; ALK protein mutant form inhibits the reaction [crizotinib binds to and results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [crizotinib results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]; crizotinib results in decreased phosphorylation of and results in decreased activity of ALK protein mutant form
CTD PMID:20979473, PMID:21030459, PMID:21502504, PMID:21767331, PMID:21791641, PMID:21812414, PMID:21838707, PMID:21948233, PMID:22034911, PMID:22072639, PMID:22129595, PMID:22235099, PMID:22277784, PMID:22286764, PMID:22553343, PMID:22659414, PMID:22789543, PMID:22912387, PMID:23104988, PMID:29458018 NCBI chr 6:22,696,415...23,203,791
Ensembl chr 6:22,696,397...23,203,775
JBrowse link
G Bcl2l11 BCL2 like 11 increases expression
multiple interactions
affects response to substance
ISO crizotinib results in increased expression of BCL2L11 protein
BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of BCL2L11 protein]
BCL2L11 protein affects the susceptibility to crizotinib
CTD PMID:22729845 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions
ISO crizotinib results in decreased expression of BIRC2 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC2 protein]
CTD PMID:22729845 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
ISO crizotinib results in decreased expression of BIRC5 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC5 protein]
CTD PMID:22729845 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Cacna1c calcium voltage-gated channel subunit alpha1 C decreases activity ISO crizotinib results in decreased activity of CACNA1C protein CTD PMID:23707608 NCBI chr 4:150,635,808...151,270,790
Ensembl chr 4:150,641,066...150,829,913
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
increases activity
ISO BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased cleavage of CASP3 protein]
[crizotinib co-treated with 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one] results in increased cleavage of CASP3 protein
crizotinib results in increased activity of CASP3 protein
CTD PMID:22729845, PMID:22789543, PMID:23707608 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 increases activity ISO crizotinib results in increased activity of CASP7 protein CTD PMID:23707608 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 increases cleavage ISO Crizotinib results in increased cleavage of CASP8 protein CTD PMID:31706006 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Cd44 CD44 molecule (Indian blood group) decreases expression ISO crizotinib results in decreased expression of CD44 mRNA; crizotinib results in decreased expression of CD44 protein CTD PMID:22973962 NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
JBrowse link
G Cda cytidine deaminase decreases expression
multiple interactions
ISO crizotinib results in decreased expression of CDA protein
[crizotinib results in decreased expression of CDA protein] which results in increased susceptibility to gemcitabine
CTD PMID:22973962 NCBI chr 5:156,703,579...156,734,541
Ensembl chr 5:156,703,579...156,734,541
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein CTD PMID:22683780 NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
JBrowse link
G Egf epidermal growth factor multiple interactions
decreases response to substance
ISO EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to crizotinib] CTD PMID:22553343 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
multiple interactions
ISO EGFR protein mutant form results in decreased susceptibility to crizotinib; EGFR protein results in decreased susceptibility to crizotinib
[EGFR protein results in increased phosphorylation of EGFR protein] which results in decreased susceptibility to crizotinib; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]
CTD PMID:21791641, PMID:22235099, PMID:22277784, PMID:22553343 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eml4 EMAP like 4 decreases stability
multiple interactions
increases mutagenesis
ISO crizotinib results in decreased stability of EML4 protein mutant form
[crizotinib results in increased mutagenesis of EML4 gene mutant form] which results in decreased susceptibility to crizotinib
CTD PMID:21502504, PMID:22912387 NCBI chr 6:6,618,370...6,674,550
Ensembl chr 6:6,619,076...6,674,554
JBrowse link
G Epcam epithelial cell adhesion molecule decreases expression ISO crizotinib results in decreased expression of EPCAM mRNA; crizotinib results in decreased expression of EPCAM protein CTD PMID:22973962 NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
JBrowse link
G F3 coagulation factor III, tissue factor increases expression ISO crizotinib results in increased expression of F3 protein CTD PMID:25569083 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Fads2 fatty acid desaturase 2 increases expression ISO crizotinib results in increased expression of FADS2 mRNA CTD PMID:23707608 NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
JBrowse link
G Fasn fatty acid synthase increases expression ISO crizotinib results in increased expression of FASN mRNA CTD PMID:23707608 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
JBrowse link
G Fshb follicle stimulating hormone subunit beta decreases secretion ISO crizotinib results in decreased secretion of FSHB protein CTD PMID:22488744 NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Crizotinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions
decreases response to substance
ISO EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:22553343 NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase increases expression ISO crizotinib results in increased expression of HMGCR mRNA CTD PMID:23707608 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 increases expression ISO crizotinib results in increased expression of HMGCS1 mRNA CTD PMID:23707608 NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
JBrowse link
G Insig1 insulin induced gene 1 increases expression ISO crizotinib results in increased expression of INSIG1 mRNA CTD PMID:23707608 NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO crizotinib results in decreased activity of KCNH2 protein CTD PMID:23707608 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases response to substance ISO KIT gene mutant form results in decreased susceptibility to crizotinib CTD PMID:22277784 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases response to substance ISO KRAS protein mutant form results in decreased susceptibility to crizotinib CTD PMID:22235099 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase decreases activity ISO crizotinib results in decreased activity of LCK protein CTD PMID:21812414 NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
JBrowse link
G Lhb luteinizing hormone subunit beta decreases secretion ISO crizotinib results in decreased secretion of LHB protein CTD PMID:22488744 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357, PMID:21502504, PMID:22034911, PMID:22553343, PMID:22683780, PMID:22729845, PMID:23104988 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; Crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; EGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]
crizotinib results in decreased phosphorylation of MAPK3 protein
CTD PMID:21266357, PMID:21502504, PMID:22034911, PMID:22553343, PMID:22683780, PMID:22729845, PMID:23104988 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase decreases activity
affects response to substance
increases response to substance
increases mutagenesis
multiple interactions
decreases phosphorylation
ISO crizotinib results in decreased activity of MET protein
MET protein affects the susceptibility to Crizotinib
MET gene mutant form results in increased susceptibility to crizotinib
crizotinib results in increased mutagenesis of MET protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [Crizotinib results in increased mutagenesis of MET protein] inhibits the reaction [Crizotinib binds to and results in decreased activity of MET protein]; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Crizotinib binds to and results in decreased activity of MET protein; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of STAT3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BCL2L11 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC2 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC5 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of XIAP protein]
CTD PMID:21266357, PMID:21405128, PMID:21812414, PMID:22233293, PMID:22683780, PMID:22729845, PMID:22948846, PMID:31639374, PMID:31706006 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Mst1r macrophage stimulating 1 receptor decreases activity ISO crizotinib results in decreased activity of MST1R protein CTD PMID:21812414 NCBI chr 8:116,686,601...116,700,132
Ensembl chr 8:116,686,601...116,700,132
JBrowse link
G Mycn MYCN proto-oncogene, bHLH transcription factor multiple interactions ISO Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein] CTD PMID:22286764 NCBI chr 6:38,222,554...38,228,419
Ensembl chr 6:38,222,555...38,228,379
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
ISO Crizotinib results in increased cleavage of PARP1 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Crizotinib results in increased cleavage of PARP1 protein]
CTD PMID:31639374, PMID:31706006 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Prom1 prominin 1 decreases expression ISO crizotinib results in decreased expression of PROM1 mRNA; crizotinib results in decreased expression of PROM1 protein CTD PMID:22973962 NCBI chr14:71,532,321...71,637,400
Ensembl chr14:71,533,063...71,637,417
JBrowse link
G Ros1 ROS proto-oncogene 1 , receptor tyrosine kinase decreases phosphorylation ISO crizotinib results in decreased phosphorylation of ROS protein mutant form CTD PMID:22617245 NCBI chr20:33,100,190...33,323,544
Ensembl chr20:33,100,191...33,323,367
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation ISO crizotinib results in decreased phosphorylation of RPS6 protein CTD PMID:22034911 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Scn5a sodium voltage-gated channel alpha subunit 5 decreases activity ISO crizotinib results in decreased activity of SCN5A protein CTD PMID:23707608 NCBI chr 8:128,169,191...128,266,681
Ensembl chr 8:128,169,191...128,266,639
JBrowse link
G Srebf2 sterol regulatory element binding transcription factor 2 increases expression ISO crizotinib results in increased expression of SREBF2 mRNA CTD PMID:23707608 NCBI chr 7:123,381,082...123,438,605
Ensembl chr 7:123,381,077...123,438,603
JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases phosphorylation
multiple interactions
ISO crizotinib results in decreased phosphorylation of STAT3 protein
[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of STAT3 protein]
CTD PMID:22034911, PMID:22553343, PMID:22683780, PMID:22729845 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Tek TEK receptor tyrosine kinase decreases activity ISO crizotinib results in decreased activity of TEK protein CTD PMID:21812414 NCBI chr 5:113,725,717...113,852,799
Ensembl chr 5:113,725,717...113,852,799
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions
decreases response to substance
ISO EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:22553343 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases response to substance ISO TWIST1 protein results in decreased susceptibility to crizotinib CTD PMID:22155737 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
G Vim vimentin decreases expression ISO crizotinib results in decreased expression of VIM protein CTD PMID:22973962 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression
multiple interactions
ISO crizotinib results in decreased expression of XIAP protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of XIAP protein]
CTD PMID:22729845 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19787
    role 19734
      application 19393
        indicator 8649
          biomarker 6423
            crizotinib 53
              rac-crizotinib 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19787
    subatomic particle 19784
      composite particle 19784
        hadron 19784
          baryon 19784
            nucleon 19784
              atomic nucleus 19784
                atom 19784
                  main group element atom 19672
                    p-block element atom 19672
                      carbon group element atom 19574
                        carbon atom 19563
                          organic molecular entity 19563
                            organic molecule 19488
                              organic cyclic compound 19285
                                organic heterocyclic compound 18410
                                  heteroarene 16447
                                    monocyclic heteroarene 13303
                                      azole 12471
                                        diazole 8126
                                          pyrazoles 1294
                                            pyrazolylpiperidine 53
                                              3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine 53
                                                crizotinib 53
                                                  rac-crizotinib 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.